Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen

Aim of this phase 2 study is to explore the safety and efficacy of thoracic re-irradiation +/- SBRT to oligometastases (\<3) followed after an interval of 2 weeks by durvalumab and ceralasertib for patients with thoracic relapses +/- oligometastases after PACIFIC or PACIFIC-like (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab) regimens.

Trial Details

NCT ID
NCT06680050
Phase
PHASE2
Sponsor
Mario Negri Institute for Pharmacological Research
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Durvalumab (MEDI4736)
  • Ceralasertib
  • radiotherapy
Locations (sample)
  • Brescia, Italy|45.53558,10.21472
  • Florence, Italy|43.77925,11.24626
  • Genova, Italy|45.21604,11.87211
  • Milan, Italy|45.46427,9.18951
  • Milan, Italy|45.46427,9.18951

Key Eligibility Criteria

  • Provision of signed, written and dated informed consent and any locally required authorization
  • Male or female aged 18 years or older
  • ECOG Performance Status of 0-2
  • Life expectancy ≥ 6 months at the start of treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →